Salute e Benessere

Galapagos signs agreement to transfer Jyseleca® business to Alfasigma

Transaction expected to close in the first quarter of 2024, subject to customary closing conditionsMichele Manto, Galapagos' Chief Commercial Officer, to join Alfasigma Mechelen, Belgium; 02 January 2024, 07:00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) and Alfasigma S.p.A. today announced that they have signed an agreement to transfer Galapagos' Jyseleca® (filgotinib) business to Alfasigma, marking a significant milestone in Galapagos' transformation into an innovative...
Nasdaq GlobeNewswire
02/01/2024

Valneva Provides Updated 2023 Financial Guidance

Saint-Herblain (France), December 29, 2023– Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the Company is modifying its financial guidance for 2023. Product sales guidance remains unchanged, as do anticipated R&D expenses. The €90 million to €110 million of other income related to proceeds from potential sale of the Company's priority review voucher (PRV), which was previously expected before year-end, is now expected in early 2024...
Nasdaq GlobeNewswire
29/12/2023

Roche enters into a definitive agreement to acquire LumiraDx's Point of Care…

The transformative point of care solution will complement Roche's centralised diagnostics portfolio across Clinical Chemistry, Immunochemistry, Coagulation and Molecular, and across multiple disease areasLumiraDx's technology integrates multiple Point of Care tests on a simple to use single instrument and brings more affordable and accessible testing to patients worldwideUnder the terms of the agreement, Roche will pay a purchase price of USD 295 million and an additional payment...
Nasdaq GlobeNewswire
29/12/2023

Total number of shares and voting rights in Zealand Pharma at December 29, 2023

Company announcement – No. 46 / 2023 Total number of shares and voting rights in Zealand Pharma at December 29, 2023 Copenhagen, Denmark, December 29, 2023–Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, in accordance with section 32 of the Danish Capital Markets Act, announces the total number of shares and voting rights in the Company at...
Nasdaq GlobeNewswire
29/12/2023

Get a Glimpse of the Future: Guangzhou CIFF 2024 to Showcase Cutting-Edge Office…

The 2024 edition will expand to utilize Area A, B and D of the Canton Fair Complex, covering a total area of over 240,000 square meters. With an estimated participation of around 1,100 companies, the event focuses on three key themes, namely boundless office, healthy seating, and diverse commercial space, offering unique insights and solutions for the evolving workspace. Furthermore, the exhibition will feature the Trendy Design Hall (Hall 5.2) and the International Brand Hall (Hall 20.2)…
PR Newswire
29/12/2023

Nexstim receives Nexstim NBS System 5 order from Distributor in Europe

Press release, Helsinki, 29 December 2023 at 10 AM (EEST)Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for an NBS System 5 from a distributor company based in Europe.Nexstim's NBS (Navigated Brain Stimulation) System 5 is CE marked and FDA approved for presurgical mapping of the speech and motor cortices of the brain. In addition to its motor and speech mapping features, this specific system also includes therapeutic capabilities that allow the system…
Nasdaq GlobeNewswire
29/12/2023

Announcement of change in the total number of votes in AB SKF

AB SKF does not hold any own shares. AB SKF does not hold any own shares. Aktiebolaget SKF (publ) Information in this press release contains information that AB SKF is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication on29 December 2023at 08.00 CET. For further information, please contact: PRESS: Carl Bjernstam, Head of Media Relations tel: 46 31-337 2517; mobile: 46 722-201 893; e-mail:carl.bjernstam@skf...
PR Newswire
29/12/2023

Oxurion Avoids Bankruptcy, Announces Board and Management Changes and Enters…

Regulated information – Inside information No bankruptcy filing Significant reduction in Working Capital costsAtlas commits to fund Oxurion's Working Capital costs (including the Preclinical GA Program) through 2024 using the existing Atlas Funding Program, under the conditions as set out belowIntent to put in place Debt Restructuring planTwo new independent directors have been co-opted to the Board, and a new CEO/CFO, who will also act as an executive board member, have been...
Nasdaq GlobeNewswire
28/12/2023

GN Store Nord announces change to the Board of Directors

Board member Ronica Wang has decided to step down from the Board of Directors of GN Store Nord A/S. Consequently, GN's Board of Directors as of today consists of Jukka Pekka Pertola (Chair), Klaus Holse (Deputy chair), Anette Weber, Hélène Barnekow, and members elected by the employees: Leo Larsen, Cathrin Inge Hansen, and Claus Holmbeck-Madsen. For further information, please contact:Investor RelationsAnne Sofie Staunsbæk Veyhe +45 45 75 85 06 Rune Sandager +45 45 75 92 57Media...
Nasdaq GlobeNewswire
28/12/2023

Global In-Vitro Diagnostics Market to Record Robust Growth, Accounting for…

Get a Sample PDF of the Report: https://www.kingsresearch.com/request-sample/in-vitro-diagnostics-market-329 Get a Sample PDF of the Report: https://www.kingsresearch.com/request-sample/in-vitro-diagnostics-market-329 The applications of IVD are diverse, covering various facets of healthcare. Crucial for disease diagnosis, IVD facilitates the identification of infectious diseases such as HIV and hepatitis, along with chronic conditions like diabetes and cancer. It is instrumental in...
PR Newswire
28/12/2023

Health On Cloud Expands Global Presence with Innovative Metaverse Medical…

Health On Cloud is focused on deploying a globally connected Virtual University Hospital consisting of (i) Meta-Versity; and (ii) Cloud Hospital. In line with WHO's vision, Health On Cloud envisions creating a world where no one is excluded from medical services. Health On Cloud is focused on deploying a globally connected Virtual University Hospital consisting of (i) Meta-Versity; and (ii) Cloud Hospital. In line with WHO's vision, Health On Cloud envisions creating a world where no one is...
PR Newswire
28/12/2023

SciBase capital markets day 2024 - save the date

During SciBase's capital markets day, Pia Renaudin, CEO since October 2023, will discuss SciBase's way forward, updated strategy and long-term goals. The presentations will focus on the USA as well as SciBase's ongoing establishment in new promising markets. During SciBase's capital markets day,Pia Renaudin, CEO sinceOctober 2023, will discuss SciBase's way forward, updated strategy and long-term goals. The presentations will focus on theUSAas well as SciBase's ongoing establishment...
PR Newswire
28/12/2023

Sequana Medical submits Premarket Approval application to US FDA for alfapump®…

PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION28 December 2023, 07:00 am CETPending FDA approval, alfapump could become the first active implantable medical device in the US for treating liver ascitesGhent, Belgium – 28 December 2023– Sequana Medical NV (Euronext Brussels: SEQUA)(the " Company " or " SequanaMedical "), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that it has submitted a Premarket...
Nasdaq GlobeNewswire
28/12/2023

XRP Healthcare and The Burnratty Investment Group Unveil Investment…

With an investment range starting at USD$300,000and reaching up to a maximum of USD$3,000,000, this venture provides a rare opportunity for investors to contribute to the expansion and enhancement of private healthcare establishments, including clinics, pharmacies, and hospitals inAfrica. The investment process is designed to be flexible, accepting contributions in Fiat, USDT, or XRP, catering to the diverse preferences of interested parties. The raised funds shall enable...
PR Newswire
28/12/2023

Jung Kwan Jang Launches a Limited-edition Red Ginseng, Marking its 124th…

Rooted in shared history and trajectory with Jung Kwan Jang, the beginning Red Ginseng Extract goes back to 1899, the 36th year of King Gojong's reign. The Korean Empire's red ginseng monopoly generated significant revenue for the imperial family, constituting over the half of the family's yearly budget. Adopting a national approach to red ginseng management, the Korean Empire paid attention to the development of processing methods for easier consumption of red ginseng, beyond traditional root…
PR Newswire
28/12/2023

Calliditas refinances existing term loan with Euro 92 million senior secured…

"Signing this four-year term loan facility ensures an extension and expansion of our access to significant non-dilutive capital. With the full FDA approval of TARPEYO®, the recent issuance of a Notice of Allowance of a second TARPEYO patent and extension of debt repayment by 3 years, we believe that Calliditas is well positioned to continue to create value through direct commercialisation efforts in the United States as well as contributions from our licensees in other jurisdictions…
PR Newswire
27/12/2023

BBS-Bioactive Bone Substitutes Plc: Merja Haikola appointed as Accountable…

BBS-Bioactive Bone Substitutes Plc, Company Announcement, 27 December 2023 at 05.45 PM (EET) Merja Haikola appointed as Accountable Director (QP) of BBS-Bioactive Bone Substitutes Plc BBS-Bioactive Bone Substitutes Plc has appointed Merja Haikola (MS Chem.) as Accountable director (QP) as of 23.12.2023. The current Quality Director Soile Hakala will leave the Company's service. Haikola has broad experience from similar positions in several companies in the pharmaceutical industry,...
Nasdaq GlobeNewswire
27/12/2023

BBS-Bioactive Bone Substitutes Plc: Financial calendar and Annual General…

BBS-Bioactive Bone Substitutes, Company announcement, 27 December 2023 at 5:00 p.m. Financial calendar and Annual General Meeting in 2024During the year 2024, BBS-Bioactive Bone Substitutes Plc (”BBS”) will publish the financial information as follows:Financial Statements Release for the year 2023 will be published on Monday 26 February 2024 at 9.00 a.m. Half-year financial report January-June 2024 will be published on Friday 30 August 2024 The Annual Report for the year 2023 will be...
Nasdaq GlobeNewswire
27/12/2023

Seegene obtains ISO45001 certification

ISO45001 involves rigorous assessments based on international standards. Therefore, obtaining this certification signifies that a company possesses an occupational health and safety management system that complies with these requirements. ISO45001 involves rigorous assessments based on international standards. Therefore, obtaining this certification signifies that a company possesses an occupational health and safety management system that complies with these requirements. British Standards...
PR Newswire
27/12/2023

NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208

ORION CORPORATIONPRESS RELEASE27 DECEMBER 2023 at 11:00 EET NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208 The NEJM Evidence has published interim data from the first part of Phase I/II CYPIDES trial evaluating the safety and efficacy of ODM-208 (or MK-5684), an investigational, oral CYP11A1 inhibitor, in heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC).Prostate cancer continues to be regulated...
Nasdaq GlobeNewswire
27/12/2023

Rx-360® Announces 2024 Board of Directors

Scott Kammer, the Rx-360® Board Chair for 2023, expressed, "I am honored and proud to serve as the next chair for Rx-360. On behalf of the Rx-360 consortium and our Board of Directors, I am also pleased to welcome Liam Keary, Amber Hollner, and Jennifer Goodman to the Board for 2024. I am extremely grateful for our outgoing Board members, Eric Berg, Reggie Jackson, Ryan Raap, and Lucy Cabral. Each of them has played a part in Rx-360's growth. A special thanks to Rob Welsh for his service as…
PR Newswire
27/12/2023

Hyloris Announces Positive Clinical Study Results for Valacyclovir Oral…

Valacyclovir is an Antiviral Medication that is Commonly Used to Treat Infections Caused by Herpes Viruses Clinical Study Demonstrates Comparable Relative Bioavailability to Valaciclovir Tablets under fasted conditionsNDA submission 1(NDA) to the U.S. Food & Drug Administration (FDA) expected in 2024Liège, Belgium – December, 26 2023 – 6PM CET – Regulated information – Inside Information - Hyloris Pharmaceuticals SA (Euronext Brussels: HYL),a specialty biopharma company...
Nasdaq GlobeNewswire
26/12/2023

Zymeworks Announces $50 Million Private Placement to EcoR1 Capital

Proceeds expected to extend cash runway into H2 2027 “We are grateful for the ongoing commitment and additional financial support from our largest stockholder, EcoR1 Capital, as we work towards making a meaningful difference for people impacted by difficult-to-treat cancers and other serious diseases” said Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks. “The proceeds from this transaction allow us to further strengthen our financial position and extend our cash runway...
Nasdaq GlobeNewswire
26/12/2023

Nanobiotix Partner LianBio Assigns Its Development and Commercialization Rights…

PARIS and CAMBRIDGE, Mass., Dec.26, 2023(GLOBE NEWSWIRE) --NANOBIOTIX(Euronext : NANO –– NASDAQ: NBTX – the '' Company ''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that partner LianBio has entered into an agreement with Janssen Pharmaceutica NV (“Janssen”), a Johnson & Johnson company, whereby LianBio has assigned to Janssen LianBio's exclusive rights to develop and...
Nasdaq GlobeNewswire
26/12/2023
Altri  Comunicati